Table 3

Clinical response and symptomatic remission outcomes in the long-term study among participants who completed dose optimization, by optimized dose (n=327)
LDX
30 mg/d (n=44) 50 mg/d (n=112) 70 mg/d (n=171) All Doses (n=327)
Clinical response, n (%) 42 (95.5) 107 (95.5) 164 (95.9) 313 (95.7a)
Symptomatic remission, n (%) 38 (86.4) 95 (84.8) 145 (84.8) 278 (85.0b)

aSee Figure 4.

bSee Figure 5.

Abbreviation: LDX lisdexamfetamine dimesylate.

Mattingly et al.

Mattingly et al. BMC Psychiatry 2013 13:39   doi:10.1186/1471-244X-13-39

Open Data